ApprovedFDA approval

Emcitate (tiratricol)

Rare Thyroid Therapeutics

Marketer take

An ultra-rare pediatric endocrine launch in MCT8 deficiency, where genetic diagnosis, pediatric endocrinology and neurology referrals, and advocacy groups drive patient finding.

Sponsor company
Rare Thyroid Therapeutics
Indication
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
Therapeutic area
Endocrinology, Rare disease
Event
FDA approval
Date
Sep 28, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move